<?xml version="1.0" encoding="UTF-8"?>
<p id="par0075">However, a recent randomized clinical trial published in China examining the efficacy and safety of the administration of 400 mg of hydroxychloroquine together with the different treatments recommended by the Chinese National Plan for Diagnosis and Treatment (INFα2a, lopinavir/ritonavir, arbidol, 
 <italic>etc.</italic>), compared to the exclusive use of the latter in 30 patients with COVID-19 infection, found no significant difference in viral load at 7 days of treatment, nor in the average hospital stay, the mean time of decrease in body temperature, radiological progression in computed tomography or adverse reactions, which, for both groups, consisted of transient diarrhoea and impaired liver function. It should be noted that the study itself indicates that the sample size is far from the number needed to achieve results with significant statistical power.
 <xref rid="bib0200" ref-type="bibr">
  <sup>17</sup>
 </xref>
</p>
